Welcome to our dedicated page for Nutriband news (Ticker: NTRB), a resource for investors and traders seeking the latest updates and insights on Nutriband stock.
Nutriband Inc. (NASDAQ:NTRB) is a pioneering health and pharmaceutical company headquartered in Oviedo, Florida, with a core focus on transdermal and topical technologies for product development. The company is well-known for its innovative approach to drug delivery, particularly through its proprietary AVERSA™ technology, which aims to prevent the abuse, misuse, diversion, and accidental exposure of transdermal patches containing drugs with abuse potential such as opioids.
Nutriband's flagship product is the AVERSA™ Fentanyl patch, which integrates its abuse-deterrent technology with an FDA-approved transdermal fentanyl patch. This breakthrough product is designed to address the serious issue of transdermal patch abuse and accidental pediatric exposure, which according to recent data, continues to result in major medical outcomes and even death. The AVERSA™ Fentanyl patch has the potential to be the first opioid patch with abuse-deterrent properties and is estimated to reach peak annual US sales of $80M - $200M.
The company's innovative approach includes a portfolio of abuse-deterrent transdermal products targeting drugs such as buprenorphine and methylphenidate, which are prone to the risk of abuse and misuse. Nutriband utilizes its proprietary taste aversion technology, which makes the patches unappealing and difficult to tamper with, thereby reducing the likelihood of recreational abuse or accidental ingestion by children.
In addition to its pharmaceutical advancements, Nutriband Inc. has expanded its portfolio through its wholly-owned subsidiary, Active Intelligence, which focuses on the manufacturing of Kinesiology Tapes and has partnered with major fitness brands like Reebok and Adidas.
Recent developments include the completion of an $8.4 million private placement to fund the commercial development of AVERSA™ Fentanyl and its anticipated NDA filing with the FDA in Q1 2025. This funding will support the pivotal laboratory and clinical studies required for regulatory approval. Nutriband intends to leverage the 505(b)(2) NDA regulatory pathway, which streamlines approval for drugs that have been previously approved, thereby reducing the need for extensive clinical trials.
For more detailed information, visit the company's website at www.nutriband.com.
Nutriband reported Q1 revenues of $408,532, highlighting a 219% YoY increase in sports tape sales via its Pocono Pharma subsidiary. The company is leveraging penetration pricing to secure deals with major brands like KT Tape, Reebok, Adidas, and New Balance.
In Q1, Nutriband completed an $8.4M private placement at $4 per share, bringing its cash position to $8,347,739 as of April 30, 2024.
The company is advancing its AVERSA line, targeting a Q1 2025 NDA filing for AVERSA Fentanyl, projected to achieve peak annual sales of $80-$200M. AVERSA Buprenorphine could reach up to $130M in annual sales.
Nutriband (NASDAQ:NTRB), a developer of transdermal pharmaceuticals and technology, will host an exclusive live investor webinar on May 30, 2024, at 4:15 p.m. ET.
Organized by RedChip Companies, the event will feature Chairman Serguei Melnik and CEO Gareth Sheridan, who will provide insights into the company's current operations and future milestones.
Investors can register for the free webinar and submit questions beforehand or during the live session.
Nutriband announced the appointment of Sergei Glinka to its board of directors. Glinka, an experienced business leader, brings a wealth of experience from his roles in major European companies. The Glinka family has invested $4.5 million in Nutriband via a private placement in April 2024, which totaled $8.4 million. Nutriband aims to use these funds to complete the FDA approval process for its AVERSA™ technology. AVERSA™, currently patented in 45 countries, is projected to reach peak annual US sales between $80 million and $200 million. The global opioid market was valued at $22.8 billion in 2022.
RedChip Companies will air interviews with Can-Fite BioPharma (NYSE American:CANF) and Nutriband Inc. (NASDAQ:NTRB) on the RedChip Small Stocks, Big Money™ show on Bloomberg TV. Pnina Fishman, Executive Chairperson and Chief Scientific Officer of Can-Fite BioPharma, discusses the company's advanced clinical stage drug development focusing on oncology and inflammatory diseases. Can-Fite has two drug candidates in advanced stages of development with registration plans agreed with the U.S. FDA and the EMA. Gareth Sheridan, Founder and CEO of Nutriband, talks about their AVERSA™ abuse-deterrent transdermal technology to address the global opioid crisis. Nutriband's lead product, AVERSA™ Fentanyl, is targeting peak annual sales of $80 million to $200 million.
FAQ
What is the current stock price of Nutriband (NTRB)?
What is the market cap of Nutriband (NTRB)?
What is Nutriband Inc.'s primary focus?
What is AVERSA™ technology?
What is the AVERSA™ Fentanyl patch?
What recent achievements has Nutriband Inc. made?
What partnerships does Nutriband Inc. have?
What are the potential market sales for AVERSA™ Fentanyl?
What is the significance of the 505(b)(2) NDA regulatory pathway for Nutriband?
How does Nutriband address accidental pediatric exposure to fentanyl patches?
What other products are in Nutriband’s development pipeline?
Where can I get more information about Nutriband Inc.?
